Pitavastatin reduces elevated IL-18 levels in Japanese subjects with hypercholesterolemia: Sub-analysis of Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN)

Journal of Atherosclerosis and Thrombosis

Volumn 18, Issue 1, 2011, Pages 8-15

  Fujioka, Yoshio ^a,b   Fukuda, Akira ^c   Ishida, Tatsuro ^b   Kagimoto, Shinji ^d   Nakamura, Yoshio ^e   Iwakura, Akane ^e   Hara, Kyoko ^e   Yamamoto, Taizo ^f   Kuroe, Akira ^g   Ohya, Michihiro ^h   Fujimoto, Shinpei ⁱ   Hamamoto, Yoshiyuki ^i,j   Honjo, Sachiko ^j   Ikeda, Hiroki ^j   Nabe, Koichiro ^j   Tsuda, Kinsuke ⁱ   Taniguchi, Ataru ^k   Tanaka, Kiyoshi ^l   Koshiyama, Hiroyuki ^i,j   Kume, Noriaki ⁱ   Hirata, Ken Ichi ^b   more..

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SAISEIKAI NAKATSU HOSPITAL   (Japan)

^d Kagimoto Diabetes Clinic   (Japan)

^e Hyogo Prefectural Amagasaki Hospital   (Japan)

^f KYOTO KATSURA HOSPITAL   (Japan)

^g Hikone Municipal Hospital   (Japan)

^h KANSAI ELECTRIC POWER CO   (Japan)

ⁱ KYOTO UNIVERSITY   (Japan)

^j Kitano Hospital   (Japan)

^k Kyoto Preventive Medical Center   (Japan)

^l KYOTO WOMEN'S UNIVERSITY   (Japan)

more..

Author keywords

Cholesterol; High sensitivity C reactive protein (hs CRP); Inflammation; Interleukin 18 (IL 18); Statin

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 18; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; REMNANT LIKE PARTICLE CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC);

EID: 79551643299     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.5942     Document Type: Article

References (35)

1. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med, 2002; 347: 1557-1565
2. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S: New markers of inflammation and endothelial cell activation: Part I. Circulation, 2003; 108: 1917-1923
3. Packard RRS, Libby P: Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem, 2008; 54: 24-38
4. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359: 2195-2207
5. Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S: An Update on the Role of Markers of Inflammation in Atherosclerosis. J Atheroscler Thromb, 2010; 17: 1-11
6. Kamemura K, Fujioka Y, Takaishi H, Takahashi A, Taniguchi T, Ishikawa Y, Yokoyama M: Chylomicron remnants upregulate CD40 expression via the ERK pathway and a redox-sensitive mechanism in THP-1 cells. Atherosclerosis, 2006; 187: 257-264
7. Mallat Z, Corbaz A, Scoazec A, Besnard S, Lesèche G, Chvatchko Y, Tedgui A: Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation, 2001; 104: 1598-1603
8. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schönbeck U: Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med, 2002; 195: 245-257
9. Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S, Bayard F, Hansson GK: Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res, 2003; 59: 234-240
10. Naito Y, Tsujino T, Fujioka Y, Ohyanagi M, Okamura H, Iwasaki T: Increased circulation interleukin-18 in patients with congestive heart failure. Heart, 2002; 88: 296-297
11. Kawasaki D, Tsujino T, Morimoto S, Fujioka Y, Naito Y, Okumura T, Masutani M, Shimizu H, Yuba M, Ueda A, Ohyanagi M, Kashiwamura S, Okamura H, Iwasaki T: Usefulness of circulating interleukin-18 concentration in acute myocardial infarction as a risk factor for late restenosis after emergency coronary angioplasty. Am J Cardiol, 2003; 91: 1258-1259
12. Yoshida M: Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb, 2003; 10: 140-144
13. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366 (9493): 1267-1278
14. Koshiyama H, Taniguchi A, Tanaka K, Kagimoto S, Fujioka Y, Hirata K, Nakamura Y, Iwakura A, Hara K, Yamamoto T, Kuroe A, Ohya M, Fujimoto S, Hamamoto Y, Honjo S, Ikeda H, Nabe K, Tsuda K, Inagaki N, Seino Y, Kume N: Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars. J Atheroscler Thromb, 2008; 15: 345-350
15. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M; JAPAN-ACS Investigators: JAPAN- ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multi-center randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin in acute coronary syndrome] study). J Am Coll Cardiol, 2009; 54: 293-302
16. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ, 2009; 338: b2376
17. Koshiyama H: The impact of statin treatment on diabetic patients. Curr Opin Investig Drugs, 2003; 4: 395-400
18. Leu HB, Chen JW, Wu TC, Ding YA, Lin SJ, Charng MJ: Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia. Clin Cardiol, 2005; 28: 423-428
19. Baldassarre D, Porta B, Camera M, Amato M, Arquati M, Brusoni B, Fiorentini C, Montorsi P, Romano S, Veglia F, Tremoli E, Cortellaro M; MIAMI Study Group: Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis, 2009; 19: 481-490
20. Yamagami H, Sakaguchi M, Furukado S, Hoshi T, Abe Y, Hougaku H, Hori M, Kitagawa K: Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients. Ultrasound Med Biol, 2008; 34: 1353-1359
21. Motomura T, Okamoto M, Kitamura T, Yamamoto H, Otsuki M, Asanuma N, Takagi M, Kurebayashi S, Hashimoto K, Sumitani S, Saito H, Kouhara H, Nshii K, Nakao M, Koga M, Sato B, Morimoto Y, Kasayama S: Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. J Atheroscler Thromb, 2009; 16: 546-552
22. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M: Cloning of a new cytokine that induces IFN-γproduction by T cells. Nature, 1995; 378: 88-91
23. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H: Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol, 2001; 19: 423-474
24. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ; AtheroGene Investigators: AtheroGene Investigators: Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation, 2002; 106: 24-30
25. Hulthe J, McPheat W, Samnegård A, Tornvall P, Hamsten A, Eriksson P: interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis, 2006; 188: 450-454
26. Zirlik A, Abdullah SM, Gerdes N, MacFarlane L, Schönbeck U, Khera A, McGuire DK, Vega GL, Grundy S, Libby P, de Lemos JA: Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol, 2007; 27: 2043-2049
27. Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, Kullberg BJ, Tack CJ, van Krieken H, Kim SH, Stalenhoef AF, van de Loo FA, Verschueren I, Pulawa L, Akira S, Eckel RH, Dinarello CA, van den Berg W, van der Meer JW: Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med, 2006; 12: 650-656
28. Okumura T, Fujioka Y, Morimoto S, Masai M, Sakoda T, Tsujino T, Kashiwamura S, Okamura H, Ohyanagi M: Chylomicron remnants stimulate release of interleukin-1β by THP-1 cells. J Atheroscler Thromb, 2006; 13: 38-45
29. Fujioka Y, Ishikawa Y: Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb, 2009; 16: 145-154
30. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, Greene WC, Valente AJ: Interleukin- 18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1- mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem, 2006; 281: 15099-15109
31. Doi T, Sakoda T, Akagami T, Naka T, Mori Y, Tsujino T, Masuyama T, Ohyanagi M: Aldosterone induces interleukin-18 rthrough endothelin-1, angiotensin II, Rho/Rhokinase, and PPARs in cardiomyocytes. Am J Physiol Heart Circ Physiol, 2008; 295: H1279-H1287
32. Espinola-Klein C, Rupprecht HJ, Bickel C, Lackner K, Genth-Zotz S, Post F, Munzel T, Blankenberg S; Athero Gene Investigators: Impact of inflammatory markers on cardiovascular mortality in patients with metabolic syndrome. Eur J Cardiovasc Prev Rehabil, 2008; 15: 278-284
33. Mitsuoka H, Toyohara M, Kume N, Hayashida K, Jinnai T, Tanaka M, Kita T: Circulating soluble SR-PSOX/ CXCL16 as a biomarker for acute coronary syndrome -comparison with high-sensitivity C-reactive protein. J Atheroscler Thromb, 2009; 16: 586-593
34. Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, Tanaka M, Ueda A, Kominami G, Kambara H, Kimura T, Kita T: Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation, 2005; 112: 812-818
35. Mitsuoka H, Kume N, Hayashida K, Inui-Hayashiada A, Aramaki Y, Toyohara M, Jinnai T, Nishi E, Kita T: Interleukin 18 stimulates release of soluble lectin-like oxidized LDL receptor-1 (sLOX-1). Atherosclerosis, 2009; 202: 176-182